Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery).
暂无分享,去创建一个
I. Porto | L. Bolognese | F. Liistro | G. Falsini | L. Ricci | G. Ventoruzzo | K. Ducci | P. Angioli | S. Grotti | F. Turini | G. Bellandi
[1] I. Porto,et al. Impact of Critical Limb Ischemia on Long-Term Cardiac Mortality in Diabetic Patients Undergoing Percutaneous Coronary Revascularization , 2013, Diabetes Care.
[2] P. Sidhu,et al. Randomized Trial of the SMART Stent versus Balloon Angioplasty in Long Superficial Femoral Artery Lesions: The SUPER Study , 2013, CardioVascular and Interventional Radiology.
[3] S. Spiliopoulos,et al. Peripheral Applications of Drug-Coated Balloons: Past, Present and Future , 2013, CardioVascular and Interventional Radiology.
[4] C. Tejos,et al. Embolization of Incompetent Pelvic Veins for the Treatment of Recurrent Varicose Veins in Lower Limbs and Pelvic Congestion Syndrome , 2013, CardioVascular and Interventional Radiology.
[5] T. Albrecht,et al. Paclitaxel-Coated Balloons Reduce Restenosis After Femoro-Popliteal Angioplasty: Evidence From the Randomized PACIFIER Trial , 2012, Circulation. Cardiovascular interventions.
[6] A. Morabito,et al. Revascularization by Angioplasty of Type D Femoropopliteal and Long Infrapopliteal Lesion in Diabetic Patients With Critical Limb Ischemia , 2012, The international journal of lower extremity wounds.
[7] A. Kastrati,et al. Paclitaxel-Coated Versus Uncoated Balloon Angioplasty Reduces Target Lesion Revascularization in Patients With Femoropopliteal Arterial Disease: A Meta-Analysis of Randomized Trials , 2012, Circulation. Cardiovascular interventions.
[8] F. Castriota,et al. Clinical evaluation of a paclitaxel-eluting balloon for treatment of femoropopliteal arterial disease: 12-month results from a multicenter Italian registry. , 2012, JACC. Cardiovascular interventions.
[9] M. Buchbinder,et al. Nitinol Stent Implantation vs. Balloon Angioplasty for Lesions in the Superficial Femoral and Proximal Popliteal Arteries of Patients With Claudication: Three-Year Follow-up From the RESILIENT Randomized Trial , 2012, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.
[10] Raimund Erbel,et al. [2011 ESC guidelines on the diagnosis and treatment of peripheral artery diseases]. , 2012, Revue medicale de Liege.
[11] M. Nobuyoshi,et al. Classification and clinical impact of restenosis after femoropopliteal stenting. , 2012, Journal of the American College of Cardiology.
[12] M. Dake,et al. Paclitaxel-Eluting Stents Show Superiority to Balloon Angioplasty and Bare Metal Stents in Femoropopliteal Disease: Twelve-Month Zilver PTX Randomized Study Results , 2011, Circulation. Cardiovascular interventions.
[13] Thomas Zeller,et al. First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease. , 2011, Journal of vascular surgery.
[14] A. Comerota,et al. Subintimal Angioplasty for Advanced Lower Extremity Ischemia due to TASC II C and D Lesions of the Superficial Femoral Artery , 2010, Vascular and endovascular surgery.
[15] A. Banning,et al. Drug-eluting balloons: what is their place on the interventionalist's shelf? , 2010, Heart.
[16] S. Nanto,et al. Long-Term Results of Endovascular Therapy With Nitinol Stent Implantation for TASC II A/B Femoro-Popliteal Artery Lesions , 2009 .
[17] R. Pakala,et al. Drug-eluting balloon: the comeback kid? , 2009, Circulation. Cardiovascular interventions.
[18] Thomas Jahnke,et al. Nitinol Stent Implantation in Long Superficial Femoral Artery Lesions: 12-Month Results of the DURABILITY I Study , 2009, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.
[19] S. Nanto,et al. Long-term results of endovascular therapy with nitinol stent implantation for TASC II A/B femoro-popliteal artery lesions: 4 years' experience. , 2009, Circulation journal : official journal of the Japanese Circulation Society.
[20] B. Hamm,et al. Inhibition of Restenosis in Femoropopliteal Arteries: Paclitaxel-Coated Versus Uncoated Balloon: Femoral Paclitaxel Randomized Pilot Trial , 2008, Circulation.
[21] C. Claussen,et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. , 2008, The New England journal of medicine.
[22] William Wijns,et al. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. , 2007, Circulation.
[23] A. Bradbury,et al. TASC II document on the management of peripheral arterial disease. , 2007, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.
[24] Jean-Paul Beregi,et al. Drug-Eluting and Bare Nitinol Stents for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery: Long-Term Results from the SIROCCO Trial , 2006, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.
[25] Johannes Lammer,et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. , 2006, The New England journal of medicine.
[26] Thomas Zeller,et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. , 2005, Journal of vascular and interventional radiology : JVIR.
[27] A. Lansky,et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. , 2004, The Journal of invasive cardiology.
[28] Gerhard Ziemer,et al. Sirolimus-Eluting Stents for the Treatment of Obstructive Superficial Femoral Artery Disease: Six-Month Results , 2002, Circulation.
[29] E J Topol,et al. Local drug delivery for the prevention of restenosis. Fact, fancy, and future. , 1994, Circulation.
[30] T. Hedner,et al. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. , 1992, Blood pressure.
[31] William Wijns,et al. A Cause for Concern , 2007 .